Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Investigators developed chimeric antigen receptors (CAR s) for expression on T cells more
than 25 years ago. When the CAR is derived from an antibody, the resultant cell should …

The genetic modification and characterization of T-cells with chimeric antigen receptors
(CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The …

Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows
promise in recent trials. Synthetic-biology-based engineering of T lymphocytes to express …

T cells have the capacity to eradicate diseased cells, but tumours present considerable
challenges that render T cells ineffectual. Cancer cells often make themselves …

Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …

Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in
cancer treatment following the impressive results in hematologic malignancies …

The clinical efficacy of chimeric antigen receptor (CAR)-redirected T cells remains marginal
in solid tumors compared with leukemias. Failures have been attributed to insufficient T-cell …

Adoptive cellular immunotherapy (ACT) employing engineered T lymphocytes expressing
chimeric antigen receptors (CARs) has demonstrated promising antitumor effects in …

For the adoptive transfer of tumor-directed T lymphocytes to prove effective, there will
probably need to be a match between the chemokines the tumor produces and the …